Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ernest Nadal, MD, PhD"'
Autor:
Esther Conde, MD, PhD, Susana Hernandez, PhD, Jose Luis Rodriguez Carrillo, MD, Rebeca Martinez, APT, Marta Alonso, APT, Daniel Curto, MD, Beatriz Jimenez, MD, Alejandra Caminoa, MD, PhD, Amparo Benito, MD, Pilar Garrido, MD, PhD, Sergi Clave, PhD, Edurne Arriola, MD, PhD, Isabel Esteban-Rodriguez, MD, PhD, Javier De Castro, MD, PhD, Irene Sansano, MD, Enriqueta Felip, MD, PhD, Federico Rojo, MD, PhD, Manuel Dómine, MD, PhD, Ihab Abdulkader, MD, PhD, Jorge Garcia-Gonzalez, MD, Cristina Teixido, PhD, Noemi Reguart, MD, PhD, Desamparados Compañ, MD, PhD, Amelia Insa, MD, Nuria Mancheño, MD, PhD, Sarai Palanca, MD, PhD, Oscar Juan-Vidal, MD, PhD, Nuria Baixeras, MD, Ernest Nadal, MD, PhD, Maria Cebollero, MD, Antonio Calles, MD, Paloma Martin, MD, PhD, Clara Salas, MD, PhD, Mariano Provencio, MD, PhD, Ignacio Aranda, MD, PhD, Bartomeu Massuti, MD, Laura Lopez-Vilaro, MD, Margarita Majem, MD, PhD, Luis Paz-Ares, MD, PhD, Fernando Lopez-Rios, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100653- (2024)
Introduction: RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RET fusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencin
Externí odkaz:
https://doaj.org/article/a3e58ca9d39948fda3972ff1d75a8f34
Autor:
Kazumi Nishino, MD, PhD, Jin-Yuan Shih, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Michelle Carlsen, MS, Tomoko Matsui, Carla Visseren-Grul, MD, Ernest Nadal, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100624- (2024)
Introduction: EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients wit
Externí odkaz:
https://doaj.org/article/5159d19b07b0438c8a46366db7862e0c
Autor:
Nadal E; Ernest Nadal, MD, PhD, and Noelia Vilariño, MD, Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; Marta Simó, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain; Valentí Navarro, BS, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; and Jordi Bruna, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain., Vilariño N; Ernest Nadal, MD, PhD, and Noelia Vilariño, MD, Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; Marta Simó, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain; Valentí Navarro, BS, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; and Jordi Bruna, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain., Simó M; Ernest Nadal, MD, PhD, and Noelia Vilariño, MD, Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; Marta Simó, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain; Valentí Navarro, BS, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; and Jordi Bruna, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain., Navarro V; Ernest Nadal, MD, PhD, and Noelia Vilariño, MD, Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; Marta Simó, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain; Valentí Navarro, BS, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; and Jordi Bruna, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain., Bruna J; Ernest Nadal, MD, PhD, and Noelia Vilariño, MD, Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; Marta Simó, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain; Valentí Navarro, BS, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; and Jordi Bruna, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Mar 01; Vol. 42 (7), pp. 859-861. Date of Electronic Publication: 2023 Dec 11.